News
Synaffix partners with SOTIO Biotech in deal worth up to $740m
Synaffix has announced that it has entered into a licensing agreement with SOTIO Biotech to expand its antibody-drug conjugate (ADC) pipeline in a deal worth up to $740m.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Synaffix has announced that it has entered into a licensing agreement with SOTIO Biotech to expand its antibody-drug conjugate (ADC) pipeline in a deal worth up to $740m.